By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Intarcia


Drug Discovery

Company News
Intarcia Strengthens Board Of Directors For Next Stage Of Growth 9/20/2017 8:51:50 AM
New Intarcia Study Evaluates Optimal Way To Switch From Daily Liraglutide Injections To ITCA 650 In Patients With Type 2 Diabetes 9/15/2017 10:01:38 AM
Intarcia And Numab AG Reach Key Milestone With Selection Of Multi-Specific Development Candidate For Autoimmune Disease 9/14/2017 7:59:50 AM
Fast-Growing Intarcia Awaits Crucial FDA Decision in New Boston HQ 5/8/2017 6:12:47 AM
Intarcia Announces FDA Filing Acceptance Of New Drug Application (NDA) For ITCA 650 For The Treatment Of Type 2 Diabetes 2/6/2017 6:23:33 AM
Intarcia And Calibr Announce Collaboration And In-Licensing Deal Aimed At Delivering A Next Generation Combination Product For Diabetes And Obesity 1/9/2017 7:18:54 AM
Bill & Melinda Gates Foundation Sends $140M to Intarcia for HIV Version of Pump 12/30/2016 7:20:55 AM
Intarcia Secures Second Close Of The Series EE Equity Financing For An Additional $206M 12/29/2016 9:50:47 AM
Intarcia Submits New Drug Application (NDA) To FDA For U.S. Marketing Approval Of ITCA 650 In Type 2 Diabetes 11/21/2016 6:41:01 AM
Week In Review: China's Luxin Invests In $215 Million Funding For Intarcia's Long-Term Diabetes Device 9/19/2016 8:10:50 AM